WeVote
Log In

Bill

Bill

S 1795

Empower Charter School Educators to Lead Act

119th Congress Introduced by Michael Bennet and 5 co-sponsors

Bill S 1795 allows pharmacists to substitute brand name epinephrine auto-injectors with alternatives, improving access to life-saving medication for allergy sufferers.

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 1795

Summary of Bill S 1795

Overview

Bill Number: S 1795
Title: Relates to the substitution of brand name epinephrine auto-injectors with alternate epinephrine auto-injectors
Status: Referred to Higher Education
Introduced: January 13, 2025
Classification: Bill

Purpose and Intent

The primary purpose of Bill S 1795 is to facilitate the substitution of brand name epinephrine auto-injectors with alternative epinephrine auto-injectors. This legislation aims to enhance access to life-saving medication for individuals at risk of severe allergic reactions (anaphylaxis) by allowing pharmacists to dispense alternative products when the prescribed brand name is not available.

Key Provisions

  • Substitution Authority: The bill grants pharmacists the authority to substitute prescribed brand name epinephrine auto-injectors with equivalent alternative products, ensuring that patients receive necessary medication without delay.
  • Equivalence Standards: The bill outlines criteria for determining the equivalence of alternative auto-injectors to ensure safety and efficacy.
  • Patient Notification: Pharmacists are required to inform patients about the substitution and provide information regarding the alternative auto-injector, including dosage and administration instructions.
  • Insurance Coverage: The bill may include provisions for insurance companies to cover the cost of alternative auto-injectors, ensuring that patients are not financially burdened by the substitution.

Affected Parties

  • Patients: Individuals who require epinephrine auto-injectors for allergy management will benefit from increased access to medication.
  • Pharmacists: The bill empowers pharmacists to make decisions regarding medication substitution, enhancing their role in patient care.
  • Healthcare Providers: Physicians and healthcare providers will need to be aware of the substitution policy to inform patients appropriately.

Procedural Aspects

  • Current Status: As of January 13, 2025, the bill has been referred to the Higher Education committee for further consideration.
  • Related Legislation: This bill is part of a broader legislative effort, with several related bills from prior sessions (S 2489, S 8189, S 3539, S 6393, S 4447) and a companion bill (A 5029) that may influence its development and potential passage.

Conclusion

Bill S 1795 seeks to improve access to essential epinephrine auto-injectors by allowing for the substitution of brand name products with alternatives. By empowering pharmacists and ensuring patient notification, the bill aims to enhance the management of anaphylaxis and improve health outcomes for individuals with severe allergies. Further discussions in the Higher Education committee will determine the bill's future trajectory.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.